

Melanoma and Skin Cancer Trials

Limited

ANNUAL REPORT 2021-22



2184
Members



111
Trial sites



36
Countries with
Members



CONQUERING MELANOMA & SKIN CANCER

Melanoma and Skin Cancer Trials

*Formerly Australian and New Zealand
Melanoma Trials Group*

ABN: 70 626 908 512

553 St Kilda Road
Melbourne VIC 3004
Australia
Ph: +61 3 9903 9022
E: hello@masc.org.au
W: masc.org.au

Stay in touch

Subscribe to our eNews: masc.org.au/e-news

Follow us on social media



@MASC_Trials



@MASCTrials



@masc_trials



@MASC_Trials



@AOMA_MASC



@AMIGOs_MASC



MASC Trials acknowledge the Traditional Owners of Country throughout Australia and recognise their continuing connection to lands, waters, and communities. We pay our respects to Aboriginal and Torres Strait Islander cultures, and to their Elders both past and present.

Contents

About us	2
Our history	4
2021/22 Snapshot	5
Recruiting trials	6
Active trials closed for recruitment	6
Year at a glance	7
Message from our Chair	8
Message from our CEO	9
Patient story: An old teacher learns a new lesson	10
Board of Directors	12
MASC Trials team	14
Patient advocacy	15
Patient story: Checking back in on a true ironman	16
Spotlight on melanoma (skin) research	18
Spotlight on Merkel cell carcinoma research	21
Spotlight on uveal melanoma research	24
Patient story: A new vision for uveal melanoma	26
Research	28
Publications	30
Events	31
Financial statement	32
Acknowledgements	33
Get involved	34
Donate to MASC Trials	35

Page 18
Spotlight on
melanoma (skin)
research



Page 26
A new vision for
uveal melanoma



Page 16
Checking back in on
a true ironman



Page 34
Get involved



Page 10
An old teacher learns
a new lesson

About us

The high-quality evidence published from our trials changes clinical practice to impact the lives of patients and improve how doctors prevent, diagnose and treat melanoma and skin cancer.

Practice-changing outcomes

Melanoma and Skin Cancer Trials Limited (MASC Trials) is Australia and New Zealand's collaborative clinical trials group committed to preventing and to finding better treatments for melanoma and skin cancer.

Working with leading researchers, MASC Trials conducts multicentre, national and international clinical trials at more than 110 institutions in Australia and overseas. Our diverse and growing portfolio includes research in the prevention, early detection and treatment of melanoma and skin cancer, including early to late phase clinical trials.

International network boosts research

Our 2,148 members throughout Australia and around the world represent the many disciplines critical to our work and strengthen the success of our clinical trials. Together, we work to reduce the burden of melanoma and skin cancer on the healthcare system.

From early engagement with consumers and researchers to develop research ideas, through to the publication of results, we work cooperatively to provide a range of clinical trial services. We value the experiences of consumers and our collaborative approach ensures their unique perspectives are considered in clinical trial prioritisation and development.

Our endorsement of research projects and clinical trial protocols provides them with a badge of quality, increases their chance of being funded, and has been a key factor in our success.

Supported by leading institutions and generous donors

MASC Trials continues to be supported by the Australian Government via Cancer Australia, Monash University and the generosity of our industry partners and donors.

Our academic affiliation with Monash University and its Melanoma and Skin Cancer Research Centre within the School of Public Health and Preventive Medicine, enhances our research activities. As one of Australia's top universities, Monash University provides access to state-of-the-art facilities, leading academics and excellent support services.

Our services

We assist researchers across all facets and stages of clinical trials, including:

- Research concept development
- Protocol development
- Trial budget preparation
- Peer review of trial design via the MASC Trials Discipline-Specific Advisories
- Feasibility evaluation and site selection
- Biostatistics and statistical modelling
- Health economic modelling
- Quality of Life and patient report outcome modelling
- Consumer engagement and advocacy
- Grant writing support
- Endorsement of clinical trials
- Access to local and international recruitment networks
- Mentoring opportunities for researchers
- Trial and research project management

The high-quality evidence published from our trials changes clinical practice to impact the lives of patients and improve how doctors prevent, diagnose and treat melanoma and skin cancer.

Our vision, mission & values

Vision

**Eliminate melanoma and
skin cancer**

Mission

**We work collaboratively with
world-leading researchers to
deliver clinical trials that improve
melanoma and skin cancer
outcomes**

Values

**Collaboration
Compassion
Innovation
Leadership**

Our History

1999	2000	2002	2008	2009
ANZMTG Founded	First ANZMTG trial developed with TROG	ANZMTG Executive Committee formed, based at Royal Prince Alfred Hospital in Sydney	Cancer Australia core funding secured via University of Sydney First Annual Scientific Meeting	First national clinical trial grant secured
2010	2011	2014	2015	2016
ANZMTG transitions with MIA to the Poche Centre, Sydney	First international partnership 500 members reached	First project management of a medical oncology clinical trial	Recipient of National Excellence Award	1,000 members reached
2017	2018	2019	2020	2021
First NHMRC clinical trial grant secured Formation of the Australasian Merkel Cell Carcinoma Interest Group (AMIGOs) and the Australasian Ocular Melanoma Alliance (AOMA)	Discipline-Specific Advisories (DSA) launched to support trial development First MRFF clinical trial grant secured ANZMTG incorporates as Melanoma and Skin Cancer Trials Limited (MASC Trials)	Research agreement formed with Monash University MASC Trials transitions to Monash University, based in Melbourne First AOMA Summit	New MASC Trials website launched 1,957 members reached	Virtual Annual Scientific Meeting held 2,148 members reached Skin Cancer DSA formed Consumer Advisory Panel formed

2021/22 Snapshot



800

**Participants Enrolled
in Trials**



5

Recruiting Trials



7

**Active Trials Closed
for Recruitment**



111

Trial Sites



11

**Participating
Countries**



185

New Members



2148

Total Members



36

**Countries with
Members**



13

MASC Trials Staff



6

Grants Submitted



4

Grants Awarded



11

Publications



15

**Conferences and
Events**

Recruiting trials

Melanoma

IMAGE

Sites activated: 10
Participants recruited: 330
Still recruiting as of 30 June 2022

MelMarT-II

Sites activated: 46
Participants recruited: 718
Still recruiting as of 30 June 2022

Merkel cell carcinoma

GoTHAM

Sites activated: 6
Participants recruited: 8
Still recruiting as of 30 June 2022

I-MAT

Sites activated: 17
Participants recruited: 45
Still recruiting as of 30 June 2022

Uveal melanoma

Uveal Melanoma Registry

Sites activated: 4
Participants recruited: 84
Still recruiting as of 30 June 2022

Research study

Improving melanoma and skin cancer awareness in regional and rural Australia

133 media items
60 social media posts

Trials in start-up

SiroSkin

Skin cancer in organ transplant recipients
Estimated study start date: November 2022

SOCRATES

Melanoma treated with an immune checkpoint inhibitor
Estimated study start date: November 2022

Active trials closed for recruitment

Melanoma

WBRTMel

Sites: 39
Participants: 215
Closed recruitment: September 2017

EAGLE FM

Sites: 15
Participants: 101
Closed recruitment: March 2020

CHARLI

Sites: 10
Participants: 52
Closed recruitment: December 2021

RTN2

Sites: 23
Participants: 50
Closed recruitment: February 2020

MelMarT Pilot

Sites: 20
Participants: 400
Closed recruitment: August 2016

Lentigo maligna

RADICAL

Sites: 10
Participants: 126
Closed recruitment: December 2021


Skin cancer

SMARTI

Sites: 2
Participants: 214
Closed recruitment: May 2021

Year at a glance

Date	Events
July 2021	<ul style="list-style-type: none"> I-MAT trial opens second regional satellite site in Mackay
August 2021	<ul style="list-style-type: none"> MelMarT-II trial opens its first site in the Netherlands Patients approached via Cancer Council Victoria for IMAGE trial GoTHAM trial enrolled 5th participant
September 2021	<ul style="list-style-type: none"> IMAGE trial opens first regional site at FNQH Cairns CombIRT trial results published in <i>Clinical and Translational Radiation Oncology</i> New Board member appointed - Prof Michael Kimlin MASC Trials appoints its first Marketing and Communications Manager, Merrin Morrison
October 2021	<ul style="list-style-type: none"> New Board member appointed – Mary Tsouvalakis First Skin Cancer Discipline-Specific Advisory meeting, chaired by Prof Kiarash Khosrotehrani
November 2021	<ul style="list-style-type: none"> MASC Trials hosts virtual Annual Scientific Meeting MASC Trials led research was presented at the Australasian Melanoma Conference IMAGE trial enrolls 100th participant
December 2021	<ul style="list-style-type: none"> \$2.5M SiroSkin trial MRFF grant successful Consumer Advisory Panel holds first meeting MelMarT-II trial enrolls 500th participant I-MAT trial opens first Tasmanian site
February 2022	<ul style="list-style-type: none"> New SiroSkin trial announced MASC Trials sponsors New Zealand Melanoma Summit
March 2022	<ul style="list-style-type: none"> GoTHAM and IMAGE investigator meetings
April 2022	<ul style="list-style-type: none"> Gabrielle Byars is appointed MASC Trials CEO Dr Wen Xu is appointed Chair of AMIGOs MelMarT-II trial starts collaborative agreement with SWOG USA New Board members appointed – Prof Sophia Zoungas and Sharon Van Buerle Uveal Melanoma Registry enrolls 50th participant
May 2022	<ul style="list-style-type: none"> Registrations open for the 3rd AOMA Summit The Alfred enrolls its 100th participant for the IMAGE trial
June 2022	<ul style="list-style-type: none"> MASC Trials and Melanoma Patients Australia launch joint campaign, <i>Self-Skin Checks, No Regrets</i> MelMarT-II trial opens its first site in Slovenia IMAGE trial reaches 50% recruitment milestone First MASC Trials Data and Safety Monitoring Board meeting



Message from our Chair



Melanoma and Skin Cancer Trials (MASC Trials) experienced considerable growth throughout 2021-2022, with an increase in trial activity and staffing to maximise research opportunities aimed at preventing and treating melanoma and skin cancer.

Our international collaborative trials group continued to unite a dynamic network of health professionals specialising in melanoma and skin cancer. Together, we developed, conducted, published, and promoted high-impact research on how melanoma and skin cancer is diagnosed and treated.

I would like to acknowledge Prof H. Peter Soyer, who retired from the MASC Trials Board of Directors at the end of June 2022. Peter's perspective, wisdom and internationally recognised expertise in dermatology greatly enhanced the performance of MASC Trials' Board, helping to guide our group through its recent and substantial transformation to a productive, collaborative, and widely engaged academic group. We thank him sincerely for his work with us.

To strengthen the Board's governance, four new Directors were appointed this year. We now have nine Board members who provide robust expertise from many disciplines essential to good governance and the success of our clinical trials.

I warmly welcome to the Board:

- Prof Michael Kimlin (Brisbane) brings expertise in cancer epidemiology
- Prof Sophia Zoungas (Melbourne) provides an important connection between the Melanoma and Skin Cancer Research Centre and the School of Public Health and Preventive Medicine at Monash University
- Mary Tsouvalakis (Melbourne) offers fundraising, health and medical legal expertise, and a lived experience with skin cancer
- Sharon Van Buerle (Perth) provides expertise in complex portfolios and international processes.

Throughout the year, we farewelled Cheryl-Ann Hawkins, who was seconded to the Chief Executive Officer (CEO) role in early 2021. During her time with MASC Trials, Cheryl-Ann expanded the team by creating new roles that helped to increase our clinical trials activity and embed a sound organisational framework.

“Our international collaborative trials group continued to unite a dynamic network of health professionals specialising in melanoma and skin cancer.”

Prof Mark Shackleton
Chair, Melanoma and Skin Cancer Trials

After Cheryl-Ann's departure, the MASC Trials Board and Monash University appointed Gabrielle Byars as CEO in April 2022. Gabrielle has extensive experience in clinical research and has developed a wealth of valuable relationships and insights throughout her career. After joining MASC Trials in 2020, Gabrielle has served as a Clinical Research Associate, Research Manager, and now CEO. Across these roles, Gabrielle has displayed exemplary skills and ensured our trial portfolio continued to operate smoothly and successfully. We look forward to continued growth and excellence in performance via the guidance of such a talented leader.

With renewed funding from Cancer Australia, new projects in start-up, and the rapid pace of discovery in melanoma and skin cancer research, there is much optimism for our important clinical trials and their potential to change practice.

However, high-quality clinical trials require significant and sustained financial investment to deliver real-world results. To expand our critical work, we need to look beyond government funding to develop our partnerships and fundraising activity. To help us improve the lives of melanoma and skin cancer patients in Australia and globally, I urge you to donate to MASC Trials at masc.org.au/donate

MASC Trials is a registered charity. All donations are tax-deductible and support our clinical trials, which have a direct impact on melanoma and skin cancer patients. Your support will make a difference to their lives.



Professor Mark Shackleton MBBS PhD FRACP
Chair, Melanoma and Skin Cancer Trials Limited
Director of Oncology, Alfred Health
Professor of Oncology, Monash University
Clinical Research Fellow, Victorian Cancer Agency

Message from our CEO



Despite the ongoing pandemic, our portfolio of clinical trials and research expanded in 2021-2022. Patient recruitment increased with **800 new participants** enrolled in **13 active trials** (open and closed to recruitment) at **111 sites** across **11 countries**.

These achievements are testament to the fantastic work of our investigators and their teams throughout the world.

Providing equitable access to trials remains a high priority for MASC Trials. We have focused on opening trial sites in regional towns to gain a better representation of the community and provide regional and rural Australians with access to breakthroughs in cancer treatment. Our Merkel cell carcinoma I-MAT trial and melanoma IMAGE trial are now open in a number of regional centres.

Although MASC Trials has delivered clinical trials for 22 years, our move to Monash University in 2019 marked the beginning of a new phase during which we have significantly grown our research portfolio and staffing. The CEOs who preceded me supported this evolution and I particularly thank outgoing CEO, Cheryl-Ann Hawkins, for her support and guidance as I transitioned from the Research Manager into the CEO role.

“We have focused on opening trial sites in regional towns to gain a better representation of the community and provide regional and rural residents with access to breakthroughs in cancer treatment.”

Gabrielle Byars
CEO, Melanoma and Skin Cancer Trials

During the year, new roles were created and we now employ a Marketing and Communications Manager to help raise awareness of our important research. Several new skilled Clinical Research Associates and Clinical Data Managers were also recruited to support our investigators. I welcome the following staff to their new roles and to the team:

- Dr Sandra Vargas, Research Manager (formerly Senior Clinical Data Manager)
- Merrin Morrison, Marketing and Communications Manager
- Sharon Jones, Senior Clinical Research Associate
- Louise Gonzales, Clinical Research Associate
- Ayeshini Sella Hewage, Clinical Trials Assistant (formerly Administrative Assistant)
- Daniel Ariza Ospino, Clinical Data Manager
- Lucas Skewis, Clinical Data Manager

Our membership, which spans from healthcare professionals working in clinical trials to consumers, continued to grow with **2,148 members** now representing **36 countries**.

As the demand for our high-quality clinical trials continues to grow, we need to secure new funding sources so that we can expand our research portfolio. With the Board's support, I am now focused on establishing our fundraising capabilities so that we can deliver clinical trials that directly impact the lives of patients with melanoma and skin cancer. I encourage you to donate to MASC Trials at masc.org.au/donate

Gabrielle Byars BScBiochem MBioMedSci
Chief Executive Officer
Melanoma and Skin Cancer Trials Limited

An old teacher learns a new lesson

As a retired primary school teacher, Vivian (or Viv as he's known to his friends) has spent most of his adult life passing on valuable knowledge to his students. But it was a visit to his doctor that provided him with an unexpected – and lifesaving – lesson.

Having enjoyed an active upbringing in Queensland's sugarcane country, Viv – now 76 – was well aware of his increased risk for skin cancer.

Over his many years of teaching, Viv had drilled the mantra “no hat, no play” into hundreds of students and led by example, always making sure to wear a large hat and sunscreen while on yard duty.

Yet despite his vigilance, Viv had never given too much thought to the small brown mark on his chest.

“It looked like a tiny smudge – almost like a bit of dirt that I just couldn't clean off. After 10 years of being there it just became another part of my body that I never paid any attention to, like the countless other freckles, bumps and blemishes I've collected over the years,” Viv said.

But while Viv didn't pay any attention to the seemingly innocent mark, his doctor did and during a routine visit recommended Viv see a dermatologist for a skin check.

After making the 90-minute drive from his home in regional Queensland to Townsville, Viv underwent a full body scan. The results confirmed what his doctor had suspected. The small, seemingly innocuous smear was a melanoma.

“I'd ignored the thing for years and would have kept doing so right until it was too late. But thanks to the full body scan and my observant specialist, I was able to get the melanoma removed before it spread,” Viv said.

While Viv was indeed lucky, he was also acutely aware of the potential for more melanomas to appear, particularly given how many spots the scan identified – 1,735 to be precise.

Not wanting to tempt fate, Viv enrolled in the IMAGE clinical trial, which is one of the trials coordinated by Melanoma and Skin Cancer Trials.

The IMAGE trial is exploring whether regular full body photography can help reduce the number of ‘just in case’ biopsies following a melanoma diagnosis and improve patient outcomes. The trial will help to determine whether this surveillance photography, which typically costs around \$450, should be covered by Medicare.

“I joke with my wife that I'm a supermodel because I've posed for photographs in my underwear – although my photoshoots are much quicker and easier. It's all done in about 30 minutes, after which we can see how every single spot on my body is tracking and whether any have grown.”

“Being in this trial has given me so much peace of mind because I'm not leaving things up to chance or hoping someone happens to notice a small change in one of the many marks on my body,” he said.

While he formally left the classroom over 20 years ago, Viv has one important lesson he passes on at every opportunity.

“Go and get those spots checked. Everyone thinks it's not going to happen to them, or they'll get around to getting a skin check eventually, but melanoma can happen to anyone. So don't put off a skin check – make the most of the incredible medical resources we have in this country and get your skin checked!”

To learn more about the IMAGE clinical trial and how it's helping people like Viv to monitor their skin with confidence, visit masc.org.au/image





“Being in this trial has given me so much peace of mind because I’m not leaving things up to chance or hoping someone happens to notice a small change in one of the many marks on my body.”

Viv Chapman, IMAGE trial participant

Board of Directors

MASC Trials is governed by a volunteer Board of Directors, comprising experts in melanoma and skin cancer from leading health and research institutions in Australia and New Zealand. The Board also includes members from government and the business community, and patient advocates who have a lived experience with melanoma and skin cancer.



Prof Mark Shackleton
MBBS PhD FRACP
Chair, Medical Oncologist



Prof Andrew Spillane
MD FRACS BMBS BMedSci GAICD
Deputy Chair, Surgical Oncologist



Paul White
FCA FGIA CIA GAICD
Company Secretary, Patient Advocate



A/Prof Victoria Mar
MBBS PhD FACD
Dermatologist



Mr Richard Martin
MBChB FRACS ChMSurgOnc
Surgical Oncologist



Prof H. Peter Soyer
MD FACD FAAHMS
Dermatologist



Prof Michael Kimlin
BSc MSc GradDipEd PhD MAICD
Cancer Epidemiologist



Mary Tsouvalakis
BA LLBHons MPH
Lawyer



Prof Sophia Zoungas
MBBS FRACP PhD
Endocrinologist



Sharon Van Buerle
BEc GradDipAppSci
Executive

Lived experience drives Board members to make a difference

The MASC Trials Board of Directors is made up of passionate volunteers, each of whom bring a unique perspective and skillset that allows our organisation to enable practice-changing research.

There are many reasons why our Board members took on the significant responsibilities of this role, from working in the field to having a family member undergo skin cancer treatment. But for Paul White and Mary Tsouvalakis, it was a lived experience with cancer that inspired them.

Paul, Company Secretary and patient advocate, was just 18 when he had his first melanoma. Since then, he's had over 30 moles surgically removed from his body.

"When I was first diagnosed with stage II melanoma, there was a prevailing attitude of 'better safe than sorry'. This meant any suspicious mole was removed, along with large amounts of surrounding tissue if it was confirmed to be malignant," Paul said.

The many scars on Paul's body are a reminder of this approach, which has become more nuanced over recent years, thanks clinical trials such as the IMAGE and MelMarT trials.

"We're truly entering an exciting age for melanoma and skin cancer research, and I'm so fortunate to see the latest advances through my work with MASC Trials."

"As a MASC Trials patient advocate, I feel it's critical for our trial outcomes and governance to be optimised with the patient experience in mind," he said.

Mary, a lawyer with the Victorian Department of Health, was diagnosed with Hodgkin's disease when she was 16 and was not in remission until seven years later. She has also experienced basal cell carcinomas at 40 and 45 years of age.

"Medical research is the reason that people such as myself have the good fortune to be alive, so I'm incredibly privileged to be able to offer my legal expertise to the Board," Mary said.

"I hope that, in some small way, I'm able to give back and pay it forward. Through my work with MASC Trials I want to facilitate research through fundraising and other means that can create better outcomes for others."

"Over the years, I have watched many people lose their cancer battles that would have given everything for more time to do the things they loved. Each day is truly a gift and I intend to use that gift to support the MASC Trials team and their life changing research," she said.



MASC Trials team (As of 30 June 2022)



Gabrielle Byars
BScBiochem MBioMedSci
Chief Executive Officer



Dr Sandra Vargas
BSc (Hons) MS MPH PhD
Research Manager



Merrin Morrison
BBusComm GradDipBusMgmt
Marketing and Communications
Manager



Katja Loewe
MSc
Senior Clinical Research Associate



Sharon Jones
BSc (Hons) MSc
Senior Clinical Research Associate



Louise Gonzales
BAppSc
Clinical Research Associate



Simon Cumming
BSc GradDip
Clinical Data Manager



Daniel Ariza Ospino
BDS
Clinical Data Manager



Luca Skewis
BBioMedSci
Clinical Data Manager



Ayeshini Sella Hewage
BSc
Clinical Trials Assistant



Elizabeth Sadowy
CertIVBusAdmin DipAcc
Executive Assistant / Senior
Office Administrator



Dr Rory Wolfe
PhD
Biostatistician (Monash University)



Dr Alan Herschtal
PhD
Biostatistician (Monash University)

Patient advocacy



“No one knows melanoma like someone who’s lived it and that is why consumer engagement is so important in clinical trials.”

Alison Button-Sloan
Chair, MASC Trials Consumer Advisory Panel

Understanding the lived experience

Consumers are active partners in our research. Their valuable contributions help investigators to better understand the lived cancer experience and work towards patient-centred outcomes. By proactively engaging with consumers and incorporating their feedback throughout the entire clinical trial lifecycle, we are delivering real-world results that prioritise patients.

Consumer Advisory Panel

To improve our engagement with consumers we formed a new Consumer Advisory Panel (CAP) in December 2021. Led by Alison Button-Sloan, a melanoma consumer advocate with nine years’ advocacy experience, our CAP includes members from metropolitan and regional towns throughout Australia and a representative from New Zealand.

In the CAP’s first six months, the group has:

- Reviewed new research proposals prior to Board endorsement across a range of disciplines
- Provided a valuable consumer perspective on the ClinTrial Refer app and website, on which our clinical trials can be found
- Presented at the 2021 MASC Trials Annual Scientific Meeting
- Supported communication of MASC Trials research and achievements on social media

We also thank the many consumers we are in regular contact with, who are always willing to provide their valuable insight and contribute to our work, including Prof Jonathan Pincus, Wayne Lieberman, Susan Vine and Melissa Sheldon.



Alison Button-Sloan
CAP Chair, VIC
Melanoma, basal and squamous cell carcinomas



Paul White
CAP Deputy Chair, VIC
MASC Trials Board member
Melanoma



Anne Gately
NSW
Metastatic melanoma



Deborah Butler
QLD
Metastatic melanoma, basal and squamous cell carcinomas



Michelle Taylor
NSW
Uveal melanoma



Chris Wilson
VIC
Melanoma



Ron Murray
New Zealand
Metastatic melanoma, basal and squamous cell carcinomas

Checking back in on a true ironman

When we first featured the story of Bruno and his mission to complete a half-ironman while battling stage III melanoma, it struck a chord with many of our members and followers.

Given that was back in 2020, we thought it was time for an update on the young father's journey – and it's certainly been an eventful couple of years.

"It's been a real rollercoaster, but I'm very pleased to report that it's had many more ups than downs. Firstly – and most importantly – I'm still cancer free, thanks to my cutting-edge treatment that was made possible by clinical trials," Bruno said.



"Every time I get the results from my six-monthly PET scan, my family orders our favourite takeaway and my wife and I open a bottle of sparkling wine to celebrate. We don't take anything for granted these days as you never know what's around the corner."

In June of this year, Bruno took his triathlon ambitions to the next level, completing the full Ironman Cairns event: a gruelling 3.8km swim, 180km bike and 42.2km run, all completed consecutively and without rest.

Not only did Bruno finish, he placed in the top 45% of competitors, crossing the finish line in just under 12 hours.

"That was such a surreal and euphoric moment. I was in a world of pain physically, but when I realised that I'd actually done it and heard the roar of the crowd, I was absolutely over the moon. I wore my Ironman medal for that whole week and just took it all in."

But completing the Ironman brought back lots of emotions for Bruno, as it was while training for the half event that his doctor informed him that the mole on his back was a stage III-D melanoma that had spread and was now dangerously close to his lung.

"The prognosis wasn't positive, so I didn't know if I'd be able to continue with my training or make it to the event. So now, to have gone the full distance, it really makes me appreciate just how lucky I've been and how far I've come. It's very humbling."

When travel restrictions eased in early 2022, Bruno and his family were finally able to return to his birth-country of France – the first time he'd been back since his diagnosis.

"It was incredible to be home and catch up with friends and family. It was a very emotional reunion seeing my parents again, but we didn't dwell on the past or worst-case scenarios. Instead, we just focused on what really matters: coming together, spending quality time with loved ones, and being thankful for the good stuff in our lives."

So having completed an Ironman, what's next on Bruno's list?

"I'm done with big endurance events for now. I'm just happy to get out there and be in a position where I'm able to exercise. You never know what the future has in store for you or what the next scan may bring, so for now, I'm enjoying the journey. I'm soaking everything in, just like I did when I crossed that finish line in Cairns!"



“I’m still cancer free, thanks to my cutting-edge treatment that was made possible by clinical trials.”

Bruno Micciche, stage III melanoma patient

Spotlight on melanoma (skin) research

Australia's national cancer

Facts:

- 3rd most diagnosed cancer
- 17,000+ Australians diagnosed each year
- 1,300+ deaths each year



“As we don’t have sufficient evidence, melanoma surveillance photography is not used routinely during skin examinations.”

A/Prof Victoria Mar,
IMAGE trial Study Chair

02.19 IMAGE

Spotting melanoma early with surveillance photography

Early detection is one of the most effective tools in the fight against melanoma.

The IMAGE clinical trial, led by A/Prof Victoria Mar, is examining the effectiveness of early detection 2D and 3D Melanoma Surveillance Photography (MSP), which involves photographing the entire body. Close-up photos of individual skin lesions are taken at regular intervals so that sequential photos can be compared and potentially detect melanoma earlier.

MSP will be compared to standard clinical monitoring to determine which method results in fewer unnecessary biopsies in patients at high and very-high risk of melanoma.

The outcomes of the IMAGE trial will also provide the Australian Government with the high-quality evidence required to decide if MSP should be covered by Medicare. With each imaging session currently costing around \$450, MSP is out of reach for many Australians.

IMAGE trial status

This year eight new regional and metropolitan sites joined the trial, bringing the total number of sites to 10.

We enrolled 281 new participants, bringing the total to 330 out of a target enrolment of 580, and 86 were enrolled in a sub-study investigating biopsy rates prior to diagnosis of melanoma.

The IMAGE trial has been awarded \$2,416,998 from the Medical Research Future Fund’s Targeted Health System and Community Organisation Research initiative. The trial is sponsored by Monash University and is coordinated by the Melanoma and Skin Cancer Research Centre.

More information

For trial sites, investigators and resources, visit:

masc.org.au/image



“It is expected that the MelMarT-II trial results will lead to lower morbidity and guide the management of patients with high-risk primary cutaneous melanoma.”

Prof Michael Henderson,
MelMarT-II trial Co-Study Chair



“Melanoma does not discriminate and can affect the young and old living anywhere in the world, so this trial will give us the high-quality data needed for a consensus in melanoma management to inform the international medical community.”

Prof Marc Moncrieff,
MelMarT-II trial Co-Study Chair

02.18 MelMarT-II

Determining optimal surgical excision

For high-risk melanoma patients undergoing excision surgery, their doctor’s decision to use either a 1cm or 2cm excision margin could have a dramatic impact on their quality of life and survival.

A larger excision margin for melanomas on the face could lead to disfigurement, or reduced mobility if surgery is required on the hands or feet. However, if the excision margin is too small, the melanoma could return and metastasise.

Currently there is no high-quality evidence or consensus in the medical community about the optimal melanoma excision margin size for high-risk primary cutaneous melanoma.

Coordinated by MASC Trials across eight countries, the MelMarT-II trial aims to resolve this issue by investigating whether there is a difference in disease-free survival for patients treated with either a 1cm or 2cm excision margin for stage II primary cutaneous melanoma.

The phase III randomised controlled surgical trial will enrol almost 3,000 participants from sites in Australia, New Zealand, United Kingdom, the USA, Canada, the Netherlands, Sweden and Slovenia. Plans for establishing more Australian and international trial sites are underway, including sites in Ireland, United Kingdom and the USA. Leading this international trial together are Prof Michael Henderson in Australia and Prof Marc Moncrieff from the United Kingdom.

MelMarT-II trial status

This year 25 new sites joined the trial, bringing the total number of sites to 46. We enrolled 319 new participants, bringing the total to 718 out of a target enrolment of 2,998 participants.

Boosting this international effort was the activation of the trial within the USA’s National Cancer Institute’s National Clinical Trials Network (NCI-NCTN) through the SWOG Cooperative Group (collaborating with four other national cooperative groups). This development will allow for an anticipated inclusion of approximately 90 sites across the USA, adding to the trial’s existing six US sites.

The MelMarT-II trial has been awarded \$2,766,610 from the Australian National Health and Medical Research Council. Additional funding has been provided by national funding organisations in other countries, including the Canadian Institutes of Health Research, UK National Institute for Health Research Health Technology Assessment, and US National Cancer Institute.

The trial is sponsored by MASC Trials, and its collaborative partners are Peter MacCallum Cancer Centre, Norfolk and Norwich University Hospital, Canadian Cancer Trials Group, SWOG Cooperative Group, and Zuyderland Medical Center.

More information

For sites, investigators and resources, visit:

masc.org.au/melmar-t-ii





“Online educational resources, particularly for those living remotely, makes it much easier to identify unusual spots, moles or lesions.”

A/Prof Victoria Mar,
Project Lead, Improving melanoma and skin cancer awareness in regional and rural Australia

05.19 Improving melanoma and skin cancer awareness in regional and rural Australia

Educating older regional Australians about melanoma

With skin cancer rates on the rise in rural and regional Australia, MASC Trials developed a patient and consumer-centred education initiative funded by Cancer Australia to help melanoma and skin cancer patients aged 60+ living in these areas.

The project, led by A/Prof Victoria Mar, started with a consumer survey to investigate the knowledge gaps, attitudes and behaviours towards melanoma diagnosis and treatment amongst older regional and rural Australians. The project also sought to understand how access to skin cancer support could be improved, and to build a network of patient advocates.

The outcomes of the consumer survey informed the development and delivery of evidence-based education resources targeted at melanoma and skin cancer patients aged 60+ living in regional and rural areas.

Working together with Melanoma Patients Australia, the *Self-Skin Checks, No Regrets* education campaign was launched in early June 2022. The campaign encouraged rural and regional Australians aged 60+ to regularly check their skin for unusual spots, moles, or lesions, and to access the latest resources, patient stories and skin check guides online.

The campaign featured social media and media coverage, a website with a large range of evidence-based resources including educational videos, self-skin check information, patient stories, and a radio community service announcement aired throughout rural and regional Australia.

Project status


In the first month of the *Self-Skin Checks, No Regrets* education campaign, 133 items of media coverage appeared across broadcast, print and online media nationally. Across MASC Trials and Melanoma Patients Australia social media platforms, around 60 posts were uploaded linking to the *Self-Skin Checks, No Regrets* website page: melanomapatients.org.au/get-involved/self-skin-checks-no-regrets

The *Self-Skin Checks, No Regrets* campaign website resources will remain online indefinitely.

More information

For trial sites, investigators and resources, visit:

masc.org.au/awareness-regional-australia



Spotlight on Merkel cell carcinoma research

Rare, highly aggressive neuroendocrine skin cancer

Facts:

- Australia's deadliest form of skin cancer
- 300 Australians diagnosed each year
- Australia has the world's highest incidence of Merkel cell carcinoma



“We already know that immunotherapy can work very well in patients with advanced Merkel cell carcinoma but the treatment remains untested and unproven for patients with early stage disease.”

Dr Wen Xu,
AMIGOs Chair
I-MAT trial Study Chair

03.18 I-MAT

Trial to stop rare, lethal cancer in its tracks

Merkel cell carcinoma - a rare, highly aggressive neuroendocrine skin cancer that metastasises very quickly - is the most lethal form of skin cancer. Even when diagnosed early, Merkel cell carcinoma has a high risk of returning, with up to 50% of patients experiencing recurrence within two years.

Immunotherapy has revolutionised treatments for melanoma, and this approach is now being tested in early-stage Merkel cell carcinoma patients.

The I-MAT trial, led by Dr Wen Xu, is giving patients with stage I-III Merkel cell carcinoma the immunotherapy drug, Avelumab, after their initial surgery and / or radiotherapy for the cancer to improve their cure rates.

The trial will provide high-quality data to determine if a six-month regimen of Avelumab is well-tolerated and can eliminate residual microscopic cancer cells, thus reducing the risk of the cancer reoccurring and improving cure rates for patients with early-stage Merkel cell carcinoma.

This phase II, prospective, randomised, placebo-controlled, multi-institutional trial aims to enrol participants across Australia, including in regional towns.

I-MAT trial status

This year five new sites joined the trial, bringing the total number of sites to 17. We enrolled 21 new participants, bringing the total to 45 out of a target enrolment of 132.

To ensure a true representation of Merkel cell carcinoma patients in the community, the trial is open at hospitals in most Australian capital cities, as well as seven regional towns. As Queensland has the largest population of Merkel cell carcinoma patients, more regional satellite trial sites were opened this year to improve access to the trial in Mackay, Hervey Bay and Bundaberg. Rockhampton Hospital will open for recruitment in 2023.

The I-MAT trial has been awarded \$1,632,095 from the Medical Research Future Fund's Rare Cancers Initiative with top-up funding from Merck Healthcare. The trial is sponsored by MASC Trials.

More information

For trial sites, investigators and resources, visit:

masc.org.au/i-mat





“Metastatic Merkel cell carcinoma is highly responsive to radiotherapy and radiation has been shown to enhance the anti-tumour effects of immunotherapy, so there is a strong rationale that either approach could amplify the effect of immunotherapy.”

A/Prof Sandhu,
GoTHAM Trial Study Chair

10.17 GoTHAM

World first trial to test new treatment combination

Australia has the highest incidence of Merkel cell carcinoma in the world, although it is still considered a rare disease compared to other skin cancers such as melanoma.

In a world first, A/Prof Shahneen Sandhu is leading a trial that hopes to find a novel treatment combination for patients who have developed metastatic Merkel cell carcinoma. The trial is testing the immunotherapy drug, Avelumab, in combination with either radionuclide therapy or external beam radiotherapy.

The high-quality evidence gathered from this clinical trial will provide assurance to oncology teams that combining Avelumab with either radionuclide therapy or radiotherapy for metastatic Merkel cell carcinoma patients will yield the best possible results.

The Australia-wide multicentre, phase Ib/II trial is seeking to enrol up to 65 participants and has six trial sites open nationally.

GoTHAM trial status

The trial continues to operate across six sites, with plans to open sites in regional Australia. Five new participants were enrolled, bringing the total to eight. Due to the rarity of metastatic Merkel cell carcinoma, it is challenging to find the number of participants required to produce the evidence necessary for this new treatment option.


The GoTHAM trial has been awarded \$2,410,993 from the Medical Research Future Fund's Rare Cancers Initiative and top-up funding from Merck Healthcare.

More information

For trial sites, investigators and resources, visit:

masc.org.au/gotham





AMIGOs

Australasian Merkel Cell Carcinoma
Interest Group

Australasian Merkel Cell Carcinoma Interest Group

International network of Merkel cell carcinoma experts

The Australasian Merkel Cell Carcinoma Interest Group (AMIGOs) is a network of specialists across the globe working to advance the treatment and care of patients with Merkel cell carcinoma through clinical trials, and basic and translational research.

AMIGOs was formed in 2017 and is a MASC Trials special interest group. AMIGOs members include clinicians and researchers representing medical oncology, radiation oncology, surgical oncology, pathology, genetics, imaging and laboratory-based research, and consumer advocates from across Australia and globally. The group was originally led by Prof Gerald Fogarty, a radiation oncologist in Sydney. After many years of service, this year Prof Fogarty passed on the Chairperson role to Dr Wen Xu, a medical oncologist from Brisbane.

During the year, AMIGOs met twice to develop ideas for new Merkel cell carcinoma trials, discuss current research and review grant opportunities.

Australian clinical trials at international conference

This year Dr Xu attended the 2nd International Symposium of Merkel Cell Carcinoma, USA as an invited faculty member. At the conference he presented two clinical trials sponsored by MASC Trials: I-MAT and GoTHAM, and the collaborative work of AMIGOs. Dr Xu's attendance was supported by a travel grant from Merck Healthcare Australia and MASC Trials, as well as the University of Washington in Seattle where the conference was held.

Dr Xu said attending the conference was a fantastic opportunity to inform the international Merkel cell carcinoma community about treatment advances being made by Australian clinicians and researchers, as well as to learn from world experts about the latest cutting-edge developments in this rare disease.

More information

amigos.org.au



“AMIGOs is working to advance the treatment and care of patients with Merkel cell carcinoma through clinical trials, and basic and translational research.”

Dr Wen Xu,
AMIGOs Chair
I-MAT trial Study Chair

Spotlight on uveal melanoma research

Few accepted management or treatment guidelines

Facts:

- 200 Australians diagnosed each year
- 36 Australians die each year
- 25% of patients require enucleation (removal of the eye)



“The Uveal Melanoma Registry is gathering important patient data from around Australia, the UK and the USA to inform best practice and improve patient care.”

Prof Anthony Joshua
AOMA Chair
Australian Uveal Melanoma Registry
Lead Investigator

07.17 Uveal Melanoma Registry

Informing research and new treatments

Uveal melanoma is a rare and aggressive form of ocular melanoma for which there are very few accepted treatments. Uveal melanoma is clinically and biologically different from the more common skin melanoma.

This real-world registry is helping to identify predictive clinical features, document the natural history of uveal melanoma, and collect information about clinical management. The registry was made possible through our collaboration with Pulse Inframe, a real-world evidence generation, health informatics and insights company that supports our ecosystem across patients and researchers. Bristol Myers Squibb has also contributed funding to the Australian registry.

This multicentre Uveal Melanoma Registry will generate clinical and biomarker data that can be used to support drug development and pricing reimbursement. Patients can also provide direct feedback, offering a holistic view of the impact of uveal melanoma and its treatments.

Uveal Melanoma Registry status

Established in May 2021, two new sites joined the Australian registry this year, bringing the total number of sites to 4. Enrolment commenced and 84 participants were enrolled this year.

Work is underway to expand the registry, with additional sites planned for Australia and Germany, and continued collaboration with our partners in the USA and Canada.

More information

For trial sites, investigators and resources, visit:

masc.org.au/uveal-melanoma-registry-omni



Australasian Ocular Melanoma Alliance

Ocular melanoma experts collaborating to improve patient outcomes

The Australasian Ocular Melanoma Alliance (AOMA) is working to improve care and treatment of patients with ocular melanoma in Australia and around the world, and to further research into this rare form of melanoma.

AOMA was founded in 2017 and is a MASC Trials priority research special interest group.

Members include ophthalmologists, surgeons, medical and radiation oncologists, pathologists, allied health professionals, scientists, researchers and consumer representatives from across Australia and New Zealand.

During the year, AOMA met three times to develop ideas for new uveal / ocular melanoma trials, discuss current research and review grant opportunities. They also began planning for the 3rd AOMA Summit on 30 July 2022, which is Australasia's premier ocular melanoma cross-disciplinary meeting featuring presentations from leading investigators and consumers with lived experience of ocular melanoma.

National Ocular Melanoma Nurse

AOMA supported a new specialist oncology telehealth nurse to support ocular melanoma patients across Australia. The nurse provides vital support for patients in regional and rural areas who would otherwise have to travel long distances for care. Patients living around Sydney can choose between telehealth or face-to-face appointments. This year the nurse conducted 40 patient consultations.

New world-first ocular melanoma trial

The NADOM trial is a world-first neoadjuvant/adjuvant clinical trial of Darovasertib for ocular melanoma. Endorsed by AOMA and led by Prof Anthony Joshua (St Vincent's Hospital, Sydney) and Prof Mark Shackleton (Alfred Hospital, Melbourne), this trial is designed to understand the impact of the drug on *in situ* ocular tumours and hopes to prevent metastases with adjuvant treatment.

More information

aoma.org.au



A new vision for uveal melanoma

After a shock diagnosis that resulted in her losing an eye, Michelle found herself desperately seeking information about ocular melanoma. Now Michelle's joined the Uveal Melanoma Registry, so others don't have to encounter the lack of clarity that she did.

When Michelle Taylor suddenly lost much of the vision in her right eye, she assumed it was a detached retina – a relatively common issue that can be resolved with minor surgery.

It wasn't until an ophthalmologist referred her to see another specialist the very next morning – an “expert in his field” – that she began to suspect she was dealing with something more worrying than a detached retina.

A quick Google search of the doctor's name confirmed her fears. The specialist in question was an ophthalmologist who specialised in cancer.



A series of tests found that Michelle's loss of vision was a result of a large choroidal melanoma in her eye. The size and location of the tumour meant that enucleation – the removal of her eye – was necessary.

Just 10 days later, Michelle underwent the life-altering surgery.

“It all happened so quickly that the whole thing felt like a dream. I didn't really have time to fully process it until my eye was gone,” Michelle said.

“I was devastated, but my family and our sense of humour helped raise my spirits. When they visited me in hospital after the operation, they brought me a present that still makes me laugh to this day: an eraser in the shape of an eyeball.”

When Michelle Googled the name of her specialist, she didn't know that it would be the start of a long journey of searching for information about uveal melanoma.

“Aside from international references and social media support groups sharing second and third hand information on management and treatment options, there just wasn't much out there that was Australian and I really felt alone and in the dark.”

“My ophthalmologist put me in touch with Prof Anthony Joshua who gave me a clear treatment plan and suddenly I felt like I was in the right place. I felt seen.”

“It was at this time that I discovered AOMA and their website, where everything I wanted to know about my condition was in one place. It was incredible to learn that a group of Australian experts were working on treatments and management options for uveal melanoma. It was an exciting prospect and gave me hope for the future.”

Michelle enrolled in the Uveal Melanoma Registry, which is gathering patient data from sites throughout Australia, Europe and the US to support the development of novel therapies for this disease.

“It's my goal to help make a difference and ensure others don't have to go through what I did – the uncertainty and lack of information. By taking part in the Uveal Melanoma Registry and sharing my knowledge with others going through an ocular melanoma diagnosis, I hope that I can do my small part to be a beacon of shining light in their darkness.”



“By taking part in the Uveal Melanoma Registry and sharing my knowledge with others going through an ocular melanoma diagnosis, I hope that I can do my small part.”

Michelle Taylor
Uveal Melanoma Registry participant

Research

Active recruiting trials

Trial No.	Trial Name	Trial Official Title	Principal Investigator	Lead Site	Sponsor / Coordinating Centre	Funding
10.17	GoTHAM	A phase Ib/II study of combination Avelumab with peptide receptor radionuclide therapy or conventional fractionated radiotherapy in patients with metastatic Merkel cell carcinoma	A/Prof Shahneen Sandhu	Peter MacCallum Cancer Centre, VIC	MASC Trials	<ul style="list-style-type: none"> Medical Research Future Fund – Low Survival Cancers and Diseases Merck Healthcare
03.18	I-MAT	A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma	Dr Wen Xu	Princess Alexandra Hospital, QLD	MASC Trials	<ul style="list-style-type: none"> Medical Research Future Fund – Rare Cancers, Rare Diseases and Unmet Need Merck Healthcare
02.19	IMAGE	Melanoma surveillance photography to improve early detection of melanoma in very-high and high risk patients	A/Prof Victoria Mar	Alfred Hospital, VIC	Monash University / MASC Research Centre	<ul style="list-style-type: none"> Medical Research Future Fund - Targeted Health System and Community Organisation Research Grant Opportunity
02.18	MelMarT-II	A phase III, multicentre, multinational randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma	Prof Michael Henderson (Aus) Prof Marc Moncrieff (UK)	Peter MacCallum Cancer Centre, VIC	MASC Trials	<ul style="list-style-type: none"> Australian National Health and Medical Research Council
07.17	Uveal Melanoma Registry	Uveal Melanoma Registry (A Prospective Natural History Study in Uveal Melanoma)	Prof Anthony Joshua	St Vincent's Hospital, NSW	MASC Trials	<ul style="list-style-type: none"> Pulse Inframe Bristol Myers Squibb

Research study

Study No.	Study Name	Study Official Title	Principal Investigator	Lead Site	Sponsor	Funding
05.19	Supporting People with Cancer Project	Improving melanoma and skin cancer awareness in regional and rural Australia	A/Prof Victoria Mar	N/A	MASC Trials	<ul style="list-style-type: none"> Cancer Australia – Supporting People with Cancer Grant Initiative Round 11

Trials in start-up

Trial No.	Trial Name	Trial Official Title	Principal Investigator	Lead Site	Sponsor	Funding
01.21	SiroSkin	Trial of sirolimus cream in organ transplant recipients to prevent skin cancer	Prof Kiarash Khosrotehrani	Prince Charles Hospital, QLD	Monash University / MASC Research Centre	<ul style="list-style-type: none"> Medical Research Future Fund
14.20	SOCRATES	Statins and pOgression of Coronary atheRosclerosis in melanomA patients Treated with chEckpoint inhibitorS	Prof Stephen Nicholls	Monash Health, VIC	Monash University	<ul style="list-style-type: none"> Medical Research Future Fund

Active trials closed for recruitment

Trial No.	Trial Name	Trial Official Title	Principal Investigator	Lead Site	Sponsor	Funding
01.15	CHARLI	A phase Ib/II trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in patients with unresectable stage III and IV melanoma	A/Prof Shahneen Sandhu	Peter MacCallum Cancer Centre, VIC	Peter MacCallum Cancer Centre	<ul style="list-style-type: none"> Bristol Myers Squibb Amgen
04.17	SMARTI	A pilot study of an artificial intelligence system as a diagnostic aide for better skin cancer management	A/Prof Victoria Mar	Alfred Hospital, VIC	Monash University / MASC Research Centre	<ul style="list-style-type: none"> Victorian Medical Research Acceleration Fund MoleMap
02.12	RADICAL	A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused, or fails	Prof Pascale Guitera	Melanoma Institute Australia, NSW	MASC Trials	<ul style="list-style-type: none"> Cancer Australia - Priority-driven Collaborative Cancer Research Scheme
01.12	EAGLE FM	Evaluation of groin lymphadenectomy extent for metastatic melanoma – A randomised phase III trial to evaluate survival, morbidity, and quality of life	Prof Andrew Spillane	Royal North Shore Hospital, NSW	MASC Trials	<ul style="list-style-type: none"> Cancer Council NSW Friends of Mater Foundation
03.12	MelMarT (Pilot)	A phase III, multicentre, multinational randomised control trial investigating 1cm vs 2cm excision margins for primary cutaneous melanoma	Prof Michael Henderson (Aus) Prof Marc Moncrieff (UK)	Peter MacCallum Cancer Centre, VIC	MASC Trials	<ul style="list-style-type: none"> Cancer Council NSW Friends of Mater Foundation
01.09	RTN2	A randomised trial of postoperative radiation therapy following wide excision of neurotropic melanoma of the head and neck	A/Prof Matthew Foote	Princess Alexandra Hospital, QLD	MASC Trials	<ul style="list-style-type: none"> Cancer Australia Priority-driven Collaborative Research Scheme Project Grant
01.07	WBRTMeI	Whole brain radiotherapy following local treatment of intracranial metastases of melanoma – A randomised phase III trial	Prof Gerald Fogarty	St Vincent's Hospital, NSW	MASC Trials	<ul style="list-style-type: none"> Cancer Australia Priority-driven Collaborative Research Scheme Project Grant

Completed trials

Trial No.	Trial Name	Trial Official Title	Principal Investigator	Lead Site	Sponsor	Funding
02.14	Combi RT	A single-arm, phase II, multicentre study to evaluate the safety and efficacy of dabrafenib, trametinib and palliative RT in patients with stage IIIc and IV BRAF V600E/K melanoma	A/Prof Tim Wang	Westmead Hospital, NSW	MASC Trials	<ul style="list-style-type: none"> GlaxoSmithKline

Publications

- Wang, W., Smith, J. L., Carlino, M. S., Burmeister, B., Pinkham, M. B., Fogarty, G. B., Christie, D. R. H., Estall, V., Shackleton, M., Clements, A., Wolfe, R., Thao, L. T. P., Paton, E. J., Steel, V., & Williams, N. C. (2021). Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. *Clinical and Translational Radiation Oncology*, 30, 95–99. <https://doi.org/10.1016/j.ctro.2021.08.006>
- Guitera, P., Waddell, A., Paton, E., Fogarty, G. B., Hong, A., Scolyer, R. A., Stretch, J. R., O'Donnell, B. A., & Pellacani, G. (2021). A practical guide on the use of imiquimod cream to treat lentigo maligna. *Australasian Journal of Dermatology*, 62(4), 478–485. <https://doi.org/10.1111/ajd.13720>
- Ackermann, D. M., Dieng, M., Medcalf, E., Jenkins, M. C., van Kemenade, C. H., Janda, M., Turner, R. M., Cust, A. E., Morton, R. L., Irwig, L., Guitera, P., Soyer, H. P., Mar, V., Hersch, J. K., Low, D., Low, C., Saw, R. P. M., Scolyer, R. A., Drabarek, D., & Espinoza, D. (2022). Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF). *JAMA Dermatology*, 158(1), 33. <https://doi.org/10.1001/jamadermatol.2021.4704>
- Fogarty, G., Paton, E., Allen, J., Calvert, J., Dawson, T., & Australian Keratinocyte Cancer Clinical Guidelines 2019, A. G. of the. (2021). Towards better treatment outcomes for Australians with skin keratinocyte cancers - time for the patient voice? *Journal of Cancer Prevention & Current Research*, 12(5), 159–162. <https://doi.org/10.15406/jcpcr.2021.12.00472>
- Felmingham, C., MacNamara, S., Cranwell, W., Williams, N., Wada, M., Adler, N. R., Ge, Z., Sharfe, A., Bowling, A., Haskett, M., Wolfe, R., & Mar, V. (2022). Improving Skin cancer Management with ARTificial Intelligence (SMARTI): protocol for a preintervention/postintervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a specialist dermatology setting. *BMJ Open*, 12(1), e050203. <https://doi.org/10.1136/bmjopen-2021-050203>
- Schwartz, R. J., Ho, G., Gouveia, B. M., Martin, L. K., & Guitera, P. (2022). An adapter window for precise skin marking during handheld reflectance confocal microscopic scanning. *Journal of the American Academy of Dermatology*. <https://doi.org/10.1016/j.jaad.2021.11.064>
- Guitera, P., Waddell, A., Paton, E., Fogarty, G. B., Hong, A., Scolyer, R. A., Stretch, J. R., O'Donnell, B. A., & Pellacani, G. (2022). Re: Reply to letter to the editor re: "practical guide on the use of imiquimod cream to treat lentigo maligna." *Australasian Journal of Dermatology*, 63(2). <https://doi.org/10.1111/ajd.13797>
- Felmingham, C., Byars, G., Cumming, S., Brack, J., Ge, Z., MacNamara, S., Haskett, M., Wolfe, R., & Mar, V. (2022). Testing Artificial Intelligence Algorithms in the Real World: Lessons from the SMARTI Trial. *Iproceedings*, 8(1), e36902. <https://doi.org/10.2196/36902>
- Martin, A., Gouveia, B. M., Rawson, R., & Guitera, P. (2022). Complex management of lentigo maligna in the setting of chrysiasis, argyriasis, and tattoo using in vivo reflectance confocal microscopy. *The Journal of Dermatology*, 49(7), 703–709. <https://doi.org/10.1111/1346-8138.16390>
- Tran, A. D., Hong, A. M., Nguyen, M. T. H., Fogarty, G., Steel, V., Paton, E., & Morton, R. L. (2022). Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial. *Pharmacoeconomics - Open*, 6(4), 587–594. <https://doi.org/10.1007/s41669-022-00332-8>

Events



Annual Scientific Meeting

With over 170 registrations, the MASC Trials virtual Annual Scientific Meeting (ASM) on 18 November 2021 was the biggest meeting of its kind we've held to date. Chaired by MASC Trials Board Deputy Chair, Prof Andrew Spillane and Board Member, Prof H. Peter Soyer, the online event featured 14 speakers and an evolving concepts panel discussion.

The ASM program included presentations on research coordinated by MASC Trials, including updates on:

- MelMarT and MelMarT-II by Prof Michael Henderson
- RADICAL by Prof Nikolas Haas
- IMAGE by A/Prof Victoria Mar
- CHARLI and GoTHAM by A/Prof Shahneen Sandu
- I-MAT by Dr Wen Xu
- Uveal Melanoma Registry, Vision Registry and AOMA by Prof Anthony Joshua

Board Chair Prof Mark Shackleton and senior staff delivered updates on MASC Trials, and our Consumer Advisory Panel Chair, Alison Button-Sloan, presented a consumer perspective on our research.

Work has now commenced on the next MASC Trials ASM, which will be held in Brisbane on 23 March 2023, prior to the Australasian Melanoma Conference.

ASM 2023 information

masc.org.au/asm-2023



Financial statement

Melanoma and Skin Cancer Trials Limited
ABN 70 626 908 512

Statement of profit and loss and other comprehensive income for the period ended 30 June 2022.

	2022 \$
Revenue	76,385
Total Revenue	76,385
Administration	5,373
Conferences and papers	6,472
Consultants	-
Information technology	5,292
Insurance	3,731
Legal	3,200
Meetings	246
Printing	6,188
Publications	2,696
Registration and capitation fees	8,000
Salaries - Eagle FM	9,659
Sponsorship ASM 2021	10,819
Travel	4,945
Total Expenses	66,621
STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2022	
ASSETS	
CURRENT ASSETS	
Cash and cash equivalents	309,386
Accounts receivable	6,400
Prepaid expenses	-
TOTAL CURRENT ASSETS	315,786
TOTAL ASSETS	315,786
LIABILITIES	
LIABILITIES	
TOTAL LIABILITIES	-
NET ASSETS	315,786
EQUITY	
Retained earnings	315,786
TOTAL EQUITY	315,786

The full Annual Financial Report and Directors Report, for the year ending 30 June 2022, audited by Charterpoint, are available at www.acnc.gov.au/charity audited by Charterpoint, are available at www.acnc.gov.au/charity

Acknowledgments

MASC Trials recognises and thanks the many organisations that support our research. Their funding has ensured our research continues to improve the lives of melanoma and skin cancer patients.

Academic Affiliate



Australian Funding Agencies and Institutions



Industry Partners



Pro Bono Suppliers



Get involved



Become a Member

MASC Trials membership is open to anyone who has an interest in our melanoma and skin cancer clinical research, from healthcare professionals to consumers. Applying is simple and free.

As a MASC Trials Member, you can access our network of over 2,000 healthcare professionals and consumers who are committed to reducing the toll of melanoma and skin cancer through clinical research.

Your membership will also influence our Federal Government support and help us to expand our work that is improving how doctors prevent, diagnose and treat melanoma and skin cancer.

Find out more and become a Member:

masc.org.au/membership



Become a partner or sponsor

Industry partners and organisations are critical for assisting MASC Trials to deliver research that has real-world impact. Partnerships can take many forms, from sponsoring one of our scientific events, financially supporting a clinical trial, or assisting our business operations through a pro bono service.

Contact us to discuss partnership opportunities at:

hello@masc.org.au



Participate in a clinical trial

Clinical trials are essential for discovering new treatments for melanoma and skin cancer. They also provide access to breakthrough medical treatments that may benefit patients with these cancers.

For more information, visit:

www.masc.org.au/participate





Donate to MASC Trials

Your donation will directly support our clinical trials

A cure is on the horizon for Australia’s national cancer

Every year, over 17,000 Australians are diagnosed with melanoma and sadly, around 1,300 Australians will lose their life to this deadly cancer that can affect young and old.

During the past 10 years, there has been a revolution in treatments for melanoma and skin cancer. For many, a melanoma diagnosis is no longer a death sentence, but the path to being cured is not always straightforward.

The first wave of industry-driven innovation in melanoma and skin cancer treatments led by major pharmaceutical companies has receded. Although we now have a range of new therapies, we are still discovering how to optimally use these new treatments for patients and that is why clinical trials are so important.

Helping Australians access clinical trials

Thanks to the work of MASC Trials over the past 22 years, thousands of Australians have already accessed clinical trials that have improved their quality of life, prevented them from undergoing debilitating treatments, and for some, given them more time with loved ones.

More funding is urgently needed

High-quality clinical trials require significant and sustained financial investment to deliver real-world results, and as a not-for-profit organisation, MASC Trials cannot rely on government funding alone. To help improve the lives of melanoma and skin cancer patients in Australia we need your help.

Donate to clinical research

Your donation will directly support our clinical trials. You will help our world-leading researchers to improve melanoma and skin cancer outcomes, and to study innovative combined cancer treatments. Most importantly, you will make a difference to the lives of melanoma and skin cancer patients across Australia.

Donate today at: masc.org.au/donate



Join Foundation Club 100

Foundation Club 100 is our first major fundraising initiative and is seeking 100 individuals to donate \$500 or above.

As a Foundation Club 100 member, you will help to expand our clinical trials operations so that more Australians can access cutting-edge advances in and approaches to melanoma and skin cancer treatment. To acknowledge the generous support of our Foundation Club 100 donors, your name will be included in our annual report and website, unless you choose to remain anonymous.

Join Foundation Club 100: masc.org.au/foundation-club-100



Melanoma and Skin Cancer Trials

*Formerly Australian and New Zealand
Melanoma Trials Group*

ABN: 70 626 908 512

553 St Kilda Road
Melbourne VIC 3004

Australia

Ph: +61 3 9903 9022

E: hello@masc.org.au

W: masc.org.au

Stay in touch

Subscribe to our eNews: masc.org.au/e-news

Follow us on social media



@MASC_Trials



@MASCTrials



@masc_trials



@MASC_Trials



@AOMA_MASC



@AMIGOs_MASC